NVO - British Agency Supports Eli Lilly's Weight Loss Drug Mounjaro Diverging From Restrictions on Rival Novo Nordisk's Wegovy | Benzinga
Britain’s medical costs regulator, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly And Co’s (NYSE:LLY) weight-loss drug Mounjaro for certain patients with obesity.
Unlike its stance on Novo Nordisk A/S’s (NYSE:NVO) rival drug Wegovy, NICE has not imposed a time limit on Mounjaro’s usage.
NICE’s draft guidelines suggest that Mounjaro, chemically known as tirzepatide and sold as Zepbound in the U.S., should be available for patients with a body mass index (BMI) of at least 35 and one or more weight-related health conditions, such as type 2 diabetes or heart disease.
Also Read: Novo Nordisk Sues ...